Silo Pharma Targets Rheumatoid Arthritis with Latest Deal
March 16th, 2021
Psychedelics, Top Story
Every pathological condition contains disease-specific molecular tags on its vasculature, creating a kind of “zip code” that tells where it’s located in the body. There are peptides, or short chains of amino acids, that home specifically to these pathological conditions and can be used as a highly targeted therapeutic for the delivery of an active ingredient.
Silo Pharma Inc. (OTCQB: SILO) has licensed several of these homing peptides from the University of Maryland-Baltimore, where researchers have uncovered peptides targeting both central nervous system disorders—and now—autoimmune disorders.
Let’s take a look at the company’s most recent agreement with the University of Maryland-Baltimore and what it means for Rheumatoid Arthritis and the rest of its clinical pipeline.
Large & Unmet Medical Condition
Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease where the immune system attacks healthy cells in the body by mistake, causing inflammation. In particular, the condition causes inflammation in hand, wrist and knee joints, causing long-lasting tissue damage, chronic pain, unsteadiness and deformity.
There are no cures for RA but the condition can be effectively treated and managed with medications and self-management strategies. Disease-modifying antirheumatic drugs, or DMARDs, are a first-line treatment while biological response modifiers, or biologicals, are an effective second-line treatment option—but these come at a high cost.
The global market for RA drugs is forecast to reach US$36.11 billion by 2027, according to Reports and Data. RA patients receiving biologicals spend thousands of dollars per month and must deal with adverse side-effects, such as immune system suppression, which can lead to a greater possibility of infections from a wide range of diseases.
Innovative New Approach
Silo Pharma Inc. (OTCQB: SILO) recently announced an exclusive option agreement with the University of Maryland-Baltimore to explore a novel invention generally known as joint-homing peptides for use in the investigation and treatment of arthritogenic processes. By targeting inflamed endothelium, the peptides could greatly enhance RA drug delivery.
“This option gives Silo access to a unique and potentially vital therapeutic that can also act as a drug delivery platform,” said Chairman and CEO Eric Weisblum. “The ability to deliver compounds directly to targeted areas of the body with this technology could be revolutionary by increasing the efficacy of the treatment while reducing the amount of medication needed.”
The company envisions the homing peptides enhancing the therapeutic effect and decreasing the toxicity of both current and future therapies. The peptides also have the potential for the development of fusion imaging molecules and other nanoparticles to better understand arthritic pathogenesis and leverage precision imaging for diagnosis.
Beyond Rheumatoid Arthritis
Silo Pharma believes that the same homing peptides could apply to other autoimmune diseases. As a whole, the global autoimmune diseases therapeutics market is projected to reach nearly $150 billion by 2025, according to Reportlinker, while diagnostic technologies could represent another lucrative corner of the market.
Beyond these homing peptides, Silo Pharma has been focused on merging traditional therapeutics with psychedelic research to help those suffering from depression, post-traumatic stress disorder, Parkinson’s disease and other rare neurological disorders. The company’s work with the University of Baltimore-Maryland is aimed at developing targeted therapeutics.
Prior to the autoimmune option agreement, the company licensed central nervous system peptides from the University of Maryland-Baltimore, which could be essential in helping psilocybin-based therapies target diseased tissue. The company licensed the IP to Alkido Pharma Inc. (NASDAQ: AIKI) earlier this year for the treatment of cancer patients.
Silo Pharma Inc. (OTCQB: SILO) is well-capitalized after raising $4.275 million from accredited and institutional investors earlier this year. The company plans to use that capital to continue building out its therapeutic pipeline that leverages the University of Maryland-Baltimore’s peptides along with psilocybin and other drugs to treat inflammatory diseases.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.